Advertisement
The American Journal of Cardiology®
Advanced searchSave search
Rapid Communication| Volume 91, ISSUE 11, P1346-1349, June 01, 2003

Comparison of effects of abciximab versus eptifibatide on C-reactive protein, interleukin-6, and interleukin-1 receptor antagonist after coronary arterial stenting

DOI:https://doi.org/10.1016/S0002-9149(03)00327-8
Comparison of effects of abciximab versus eptifibatide on C-reactive protein, interleukin-6, and interleukin-1 receptor antagonist after coronary arterial stenting
Previous ArticleOne-year results of percutaneous myocardial revascularization for refractory angina pectoris
Next ArticleEffects of coadministration of aspirin or clopidogrel on exercise testing in patients with heart failure receiving angiotensin-converting enzyme inhibitors*
      Multiple markers of inflammation have been shown to increase after coronary stenting.
      • Gaspardone A.
      • Crea F.
      • Versaci F.
      • Tomai F.
      • Pellegrino A.
      • Chiariello L.
      • Gioffre P.A.
      Predictive value of C-reactive protein after successful coronary artery stenting in patients with stable angina.
      Am J Cardiol. 1998; 82: 515-518
      ,
      • Versaci F.
      • Gaspardone A.
      • Tomai F.
      • Crea F.
      • Chiariello L.
      • Gioffre P.A.
      Predictive value of C-reactive protein in patients with unstable angina pectoris undergoing coronary artery stent implantation.
      Am J Cardiol. 2000; 85: 92-95
      ,
      • Liuzzo G.
      • Buffon A.
      • Biasucci L.M.
      • Gallimore J.R.
      • Caligiuri G.
      • Vitelli A.
      • Altamura S.
      • Ciliberto G.
      • Rebuzzi A.G.
      • Crea F.
      • Pepys M.B.
      • Maseri A.
      Enhanced inflammatory response to coronary angioplasty in patients with severe unstable angina.
      Circulation. 1998; 98: 2370-2376
      C-reactive protein (CRP), a prototypic acute phase reactant, is induced by interleukin (IL)-6.
      • Ganter U.
      • Arcone R.
      • Toniatti C.
      • Morrone G.
      • Ciliberto G.
      Dual control of C-reactive protein gene expression by interleukin-1 and interleukin-6.
      EMBO J. 1989; 8: 3773-3779
      IL-1 induces inflammation and augments production of IL-6.
      • Ng S.B.
      • Tan Y.H.
      • Guy G.R.
      Differential induction of the interleukin-6 gene by tumor necrosis factor and interleukin-1.
      J Biol Chem. 1994; 269: 19021-19027
      Concentrations of IL-1 receptor antagonist increase concomitantly with those of IL-1 and are easier to measure than IL-1.
      • Fischer E.
      • van Zee K.J.
      • Marano M.A.
      • Rock C.S.
      • Kenney J.S.
      • Poutsiaka D.D.
      • Dinarello C.A.
      • Lowry S.F.
      • Moldawer L.L.
      Interleukin-1 receptor antagonist circulates in experimental inflammation and in human disease.
      Blood. 1992; 79: 2196-2200
      A correlation between increases in the concentrations of these markers after coronary stenting and adverse events has been demonstrated.
      • Gaspardone A.
      • Crea F.
      • Versaci F.
      • Tomai F.
      • Pellegrino A.
      • Chiariello L.
      • Gioffre P.A.
      Predictive value of C-reactive protein after successful coronary artery stenting in patients with stable angina.
      Am J Cardiol. 1998; 82: 515-518
      ,
      • Versaci F.
      • Gaspardone A.
      • Tomai F.
      • Crea F.
      • Chiariello L.
      • Gioffre P.A.
      Predictive value of C-reactive protein in patients with unstable angina pectoris undergoing coronary artery stent implantation.
      Am J Cardiol. 2000; 85: 92-95
      The present study is a prospective, randomized comparison of the effects of abciximab and eptifibatide on changes in the concentrations in blood of high-sensitivity CRP, IL-6, and IL-1 receptor antagonist during the first 24 hours after coronary stent implantation.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to American Journal of Cardiology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Register: Create an account
      Institutional Access: Sign in to ScienceDirect

      References

        • Gaspardone A.
        • Crea F.
        • Versaci F.
        • Tomai F.
        • Pellegrino A.
        • Chiariello L.
        • Gioffre P.A.
        Predictive value of C-reactive protein after successful coronary artery stenting in patients with stable angina.
        Am J Cardiol. 1998; 82: 515-518
        View in Article
        • Versaci F.
        • Gaspardone A.
        • Tomai F.
        • Crea F.
        • Chiariello L.
        • Gioffre P.A.
        Predictive value of C-reactive protein in patients with unstable angina pectoris undergoing coronary artery stent implantation.
        Am J Cardiol. 2000; 85: 92-95
        View in Article
        • Liuzzo G.
        • Buffon A.
        • Biasucci L.M.
        • Gallimore J.R.
        • Caligiuri G.
        • Vitelli A.
        • Altamura S.
        • Ciliberto G.
        • Rebuzzi A.G.
        • Crea F.
        • Pepys M.B.
        • Maseri A.
        Enhanced inflammatory response to coronary angioplasty in patients with severe unstable angina.
        Circulation. 1998; 98: 2370-2376
        View in Article
        • Ganter U.
        • Arcone R.
        • Toniatti C.
        • Morrone G.
        • Ciliberto G.
        Dual control of C-reactive protein gene expression by interleukin-1 and interleukin-6.
        EMBO J. 1989; 8: 3773-3779
        View in Article
        • Ng S.B.
        • Tan Y.H.
        • Guy G.R.
        Differential induction of the interleukin-6 gene by tumor necrosis factor and interleukin-1.
        J Biol Chem. 1994; 269: 19021-19027
        View in Article
        • Fischer E.
        • van Zee K.J.
        • Marano M.A.
        • Rock C.S.
        • Kenney J.S.
        • Poutsiaka D.D.
        • Dinarello C.A.
        • Lowry S.F.
        • Moldawer L.L.
        Interleukin-1 receptor antagonist circulates in experimental inflammation and in human disease.
        Blood. 1992; 79: 2196-2200
        View in Article
        • Braunwald E.
        Unstable angina.
        Circulation. 1989; 80: 410-414
        View in Article
        • EPISTENT Investigators
        Randomized placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade. The EPISTENT Investigators. Evaluation of Platelet IIb/IIIa Inhibitor for Stenting.
        Lancet. 1998; 352: 87-92
        View in Article
        • The ESPRIT Investigators
        Enhanced Suppression of the Platelet IIb/IIIa Receptor with Integrilin Therapy. Novel dosing regimen of eptifibatide in planned coronary stent implantation (ESPRIT).
        Lancet. 2000; 356: 2037-2044
        View in Article

      10. Dixon WJ. BMDP Statistical Software Manual. Vol. 1. Berkeley, CA: University of California Press, 1992

        View in Article
        • Buffon A.
        • Biasucci L.M.
        • Liuzzo G.
        • D’Onofrio G.
        • Crea F.
        • Maseri A.
        Widespread coronary inflammation in unstable angina.
        N Engl J Med. 2002; 347: 5-12
        View in Article
        • Lincoff A.M.
        • Kereiakes D.J.
        • Mascelli M.A.
        • Deckelbaum L.I.
        • Barnathan E.S.
        • Patel K.K.
        • Frederick B.
        • Nakada M.T.
        • Topol E.J.
        Abciximab suppresses the rise in levels of circulating inflammatory markers after percutaneous coronary revascularization.
        Circulation. 2001; 104: 163-167
        View in Article
        • Merino Otermin A.
        • Artaiz Urdaci M.
        • Bergada Garcia J.
        • Riera Sagrera M.
        • Vidal Salva B.
        • Rodriguez Fernandez A.
        Eptifibatide blocks the increase in C-reactive protein concentration after coronary angioplasty.
        Rev Esp Cardiol. 2002; 55: 186-189
        View in Article
        • Weber C.
        • Springer T.A.
        Neutrophil accumulation on activated, surface-adherent platelets in flow is mediated by interaction of Mac-1 with fibrinogen bound to alpha- IIb beta-3 and stimulated by platelet activating factor.
        J Clin Invest. 1997; 100: 2085-2093
        View in Article
        • Batchelor W.B.
        • Tolleson T.R.
        • Huang Y.
        • Larsen R.L.
        • Mantell R.M.
        • Dillard P.
        • Davidian M.
        • Zhang D.
        • Cantor W.J.
        • Sketch Jr, M.H.
        • et al.
        Randomized comparison of platelet inhibition with abciximab, tirofiban and eptifibatide during percutaneous coronary intervention in acute coronary syndromes.
        Circulation. 2002; 106: 1470-1476
        View in Article
        • Bays H.E.
        • Stein E.A.
        • Shah A.K.
        • Maccubbin D.L.
        • Mitchel Y.B.
        • Mercuri M.
        Effects of simvastatin on C-reactive protein in mixed hyperlipidemic and hypertriglyceridemic patients.
        Am J Cardiol. 2002; 90: 942-946
        View in Article
        • Farb A.
        • Weber D.K.
        • Kolodgie K.D.
        • Burke A.P.
        • Virmani R.
        Morphological predictors of restenosis after coronary stenting in humans.
        Circulation. 2002; 105: 2974-2980
        View in Article

      Article info

      Publication history

      Accepted: February 11, 2003
      Received in revised form: February 11, 2003
      Received: December 4, 2002

      Footnotes

      This study was supported by a research grant from Millenium Pharmaceuticals, Inc., Cambridge, Massachusetts.

      Identification

      DOI: https://doi.org/10.1016/S0002-9149(03)00327-8

      Copyright

      © 2003 Excerpta Medica Inc. Published by Elsevier Inc. All rights reserved.

      ScienceDirect

      Access this article on ScienceDirect
      We use cookies to help provide and enhance our service and tailor content. To update your cookie settings, please visit the for this site.
      Copyright © 2023 Elsevier Inc. except certain content provided by third parties. The content on this site is intended for healthcare professionals.


      RELX